<?xml version='1.0' encoding='utf-8'?>
<document id="23684934"><sentence text="A P-gp vesicular transport inhibition assay - optimization and validation for drug-drug interaction testing." /><sentence text="Accurate determination of potential drug-drug interaction mediated by efflux transporters (tDDI) is crucial to assess the risk of pharmacokinetic interaction and toxicity of drugs" /><sentence text=" Passive permeability and uptake transporter mediated transport are important covariates of cell-based inhibition assays that need to be taken into consideration when performing kinetic analysis of data" /><sentence text=" Vesicular uptake inhibition has been considered by regulatory agencies as a viable alternative for testing tDDI potential of low passive permeability drugs in particular" /><sentence text=" Membranes prepared from a P-gp overexpressing human cell line has superior transport properties over membranes prepared from Sf9 cells and cholesterol enriched Sf9 membranes"><entity charOffset="140-151" id="DDI-PubMed.23684934.s5.e0" text="cholesterol" /></sentence><sentence text=" P-gp expressed in this membrane effluxes N-methyl-quinidine (NMQ) with high affinity (K(m) is 3"><entity charOffset="62-65" id="DDI-PubMed.23684934.s6.e0" text="NMQ" /></sentence><sentence text="65 μM) and a high rate (V(max) is 656 pmol/mg protein/min)" /><sentence text=" Digoxin, vinblastine and paclitaxel, established P-gp substrates inhibited transport of NMQ with estimated K(i) values of 250, 0"><entity charOffset="1-8" id="DDI-PubMed.23684934.s8.e0" text="Digoxin" /><entity charOffset="10-21" id="DDI-PubMed.23684934.s8.e1" text="vinblastine" /><entity charOffset="26-36" id="DDI-PubMed.23684934.s8.e2" text="paclitaxel" /><entity charOffset="89-98" id="DDI-PubMed.23684934.s8.e3" text="NMQ" /><pair ddi="false" e1="DDI-PubMed.23684934.s8.e0" e2="DDI-PubMed.23684934.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23684934.s8.e0" e2="DDI-PubMed.23684934.s8.e1" /><pair ddi="false" e1="DDI-PubMed.23684934.s8.e0" e2="DDI-PubMed.23684934.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23684934.s8.e0" e2="DDI-PubMed.23684934.s8.e3" /><pair ddi="false" e1="DDI-PubMed.23684934.s8.e1" e2="DDI-PubMed.23684934.s8.e1" /><pair ddi="false" e1="DDI-PubMed.23684934.s8.e1" e2="DDI-PubMed.23684934.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23684934.s8.e1" e2="DDI-PubMed.23684934.s8.e3" /><pair ddi="false" e1="DDI-PubMed.23684934.s8.e2" e2="DDI-PubMed.23684934.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23684934.s8.e2" e2="DDI-PubMed.23684934.s8.e3" /></sentence><sentence text="1 and 0" /><sentence text="6 μM, respectively" /><sentence text=" A panel of 11 drugs that have been listed by regulatory agencies as reference inhibitors were used to validate the assay to predict clinical inhibition potential" /><sentence text=" All the drugs that have been implicated in P-gp mediated DDI were found to be inhibitors in a relevant concentration range" /><sentence text="" /></document>